USPTO Art Unit 1619 Prosecution Statistics

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19272053BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSJuly 2025January 2026Allow600NoNo
19182602Cosmetic FormulationApril 2025August 2025Allow410NoNo
19170092TRIPTOLIDE FORMULATIONSApril 2025January 2026Allow1011NoNo
19169843USE OF VARENICLINE FOR TREATING OCULAR CONDITIONSApril 2025February 2026Allow1021NoNo
19098518EXTRACELLULAR MATRIX HYDROGEL MICROSPHERE, AND PREPARATION METHOD AND APPLICATION THEREOFApril 2025August 2025Allow501NoNo
19077514COMPOSITION FOR HAIR PROTECTION OR HAIR STRENGTHENINGMarch 2025August 2025Allow510NoNo
19037073ORGANIC DENTAL GUM AND METHOD OF FABRICATING THE DENTAL GUMJanuary 2025August 2025Allow601NoNo
18971812TREATED OSSEOUS PARTICULATE FLUFF COMPOSITIONDecember 2024August 2025Abandon810NoNo
18960204MINERAL COMPONENT EXTRACT FROM BORYEONG MUD, METHOD FOR EXTRACTING THE SAME, AND COSMETIC COMPOSITION CONTAINING BORYEONG MUD MINERAL EXTRACTNovember 2024August 2025Allow911NoNo
18957812ECO-FRIENDLY AND BIOCOMPATIBLE HYBRID NANOMATERIALS IN SUNSCREENNovember 2024August 2025Allow911YesNo
18953754SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONSNovember 2024March 2026Abandon1621NoNo
18934892USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERSNovember 2024July 2025Allow910NoNo
188969543D PRINTED BONE DEFECT REPAIR SCAFFOLD LOADED WITH EXTRACELLULAR MATRIX OF MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOFSeptember 2024May 2025Abandon810NoNo
18895498PHARMACEUTICAL COMPOSITIONS OF CABOTEGRAVIRSeptember 2024September 2025Abandon1221NoNo
18822564Dry Powdered FormulationsSeptember 2024August 2025Abandon1111NoNo
18841788DOUBLE-CROSSLINKED FIBRIN GEL, RAW MATERIAL COMPOSITION AND KIT THEREOF, AND APPLICATION THEREOFAugust 2024June 2025Allow910NoNo
18811158METHODS FOR FIXING HAIR AND SKINAugust 2024November 2024Allow310NoNo
18775629AMINO ACID BASED SALTS, COMPOSITIONS AND METHODS FOR TREATING SKIN AND IMPROVING SKIN REJUVENATION AND LONGEVITYJuly 2024January 2026Abandon1821NoYes
18766716METHOD FOR TREATING CANCER CELLS WITH A CU/AG PARTICLE COMPOSITIONJuly 2024September 2024Allow200YesNo
18763376Use of an arsenic compound for treating a short or long cytokine storm in various autoimmune/inflammatory diseases in humans or animalsJuly 2024October 2025Abandon1520NoNo
18669051COMPOSITIONS AND METHODS FOR SUNLESS TANNINGMay 2024July 2024Abandon200NoNo
18659750TRANSDERMAL CANNABIDIOL DELIVERY DEVICEMay 2024April 2025Allow1121YesNo
18643595TOPICAL PHARMACEUTICAL COMPOSITIONSApril 2024August 2024Allow410NoNo
18639137ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONSApril 2024March 2026Abandon2320YesNo
18631545MODIFIED RELEASE COMPOSITION OF ORLISTAT AND ACARBOSE FOR THE TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERSApril 2024October 2025Allow1821YesNo
18624746BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSApril 2024September 2024Allow510NoNo
18625137Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulatorsApril 2024January 2026Abandon2111NoNo
18625131Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators.April 2024December 2025Abandon2111NoNo
18625181Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulatorsApril 2024March 2026Abandon2311NoNo
18616121Methods of treating or reducing symptoms of nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation via combination therapy with allosteric modulators and phenethylamines.March 2024September 2025Abandon1821NoNo
18616089Methods of treating or reducing symptoms of brain cancer such as glioma and glioblastoma via combination therapy with allosteric modulators and phenethylamines.March 2024June 2025Abandon1521NoNo
18607763FISH-DERIVED PEPTIDOGLYCAN RECOGNITION PROTEIN MUTANTAND APPLICATION THEREOFMarch 2024August 2024Allow510NoNo
18606551CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGSMarch 2024August 2024Allow501NoNo
18606678PEDIATRIC POWDER FOR ORAL SUSPENSION CONTAINING ANTIVIRAL AGENT AND METHOD FOR THE PREPARATION THEREOFMarch 2024September 2025Allow1821NoNo
18602710MULTISTAGE CALCINATION METHOD FOR MAKING HOLLOW SILICA SPHERESMarch 2024August 2024Allow510YesNo
18599582METHOD FOR DECREASING COLORECTAL CANCER CELLSMarch 2024June 2024Allow300YesNo
18685970CRYSTALLINE FORMS OF METHYL 2-[2-[2-BROMO-4-FLUORO-5-[3-METHYL-2,6-DIOXO-4-(TRIFLUOROMETHYL)PYRIMIDIN-1-YL]PHENOXY]PHENOXY]-2-METHOXY-ACETATEFebruary 2024February 2026Abandon2300NoNo
18586253BODY INK COMPOSITIONS AND APPLICATORSFebruary 2024July 2025Allow1631NoNo
18583657METHODS FOR RAISING NITRIC OXIDE AND REDUCTION OF URIC ACIDFebruary 2024March 2025Abandon1320NoNo
18437042WATER-BASED NAIL POLISHFebruary 2024December 2025Abandon2210NoNo
18435068SOLANUM LYCOPERSICUM SEED OIL FREEZE-DRIED POWDER WITH WHITENING EFFICACY, COMPOSITION, AND PREPARATION METHOD AND APPLICATION THEREOFFebruary 2024June 2025Allow1621NoNo
18432437POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATIONFebruary 2024May 2025Abandon1510NoNo
18430750METHOD AND COMPOSITION FOR LOWERING TOTAL SYSTEMIC CHOLESTROL, LDL CHOLESTEROL, AND NON-HDL CHOLESTEROLFebruary 2024February 2026Abandon2541YesNo
18431324Polymer Coatings Containing Drug Powder Of Controlled MorphologyFebruary 2024October 2025Abandon2010NoNo
18428005COMPLEXES OF WHEY PROTEIN MICELLES AND PECTIN AND BODY MUSCLE PROTEIN SYNTHESISJanuary 2024March 2026Abandon2520NoYes
18423908DRY EYE TREATMENTSJanuary 2024August 2025Abandon1801NoNo
18417229CROSSLINKED ORGANOSILICON RESIN, A METHOD FOR PRODUCING SAME, AND A COSMETICJanuary 2024February 2026Allow2500NoNo
18418010TREATMENT OF DEPRESSIONJanuary 2024July 2025Abandon1820NoNo
184144459-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024March 2024Allow200NoNo
184144429-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024May 2024Allow401NoNo
18410155EVA SEGMENTED INTRAVAGINAL RINGS CONTAINING PROGESTERONEJanuary 2024December 2025Abandon2420NoNo
18402953ULTRAHIGH DUCTILITY, NOVEL Mg-Li BASED ALLOYS FOR BIOMEDICAL APPLICATIONSJanuary 2024December 2025Allow2310NoNo
18400069PHARMACEUTICAL FORMULATIONS OF NAPROXEN FOR SOFT GEL ENCAPSULATION AND COMBINATIONS THEREOFDecember 2023December 2025Allow2420NoNo
18392013COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OVERDOSE AND REWARD-BASED DISORDERSDecember 2023December 2025Abandon2410NoNo
18392008COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDERDecember 2023December 2025Abandon2410NoNo
18545415SACCHARIDE-BASED ORAL MUCOADHESIVE DELIVERY SYSTEM FOR NEUROTROPHIC AND NEUROPROTECTIVE COMPOSITIONSDecember 2023April 2025Abandon1610NoNo
18543203ENHANCED FORMULATIONS, COMPOSITIONS AND METHODS FOR PEST CONTROLDecember 2023September 2025Allow2131NoNo
18542059BONE REGENERATION MATERIAL HAVING A COTTON-WOOL LIKE STRUCTURE FORMED OF A PLURALITY OF ELECTROSPUN FIBERSDecember 2023February 2025Abandon1411NoNo
18541054PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOFDecember 2023February 2025Abandon1410NoNo
18541570INTRAOCULAR PRESSURE REDUCTION WITH INTRACAMERAL BIMATOPROST IMPLANTSDecember 2023December 2025Abandon2401NoNo
18541995LONG-TERM STABLE LIVE FECAL MICROBIOTA COMPOSITIONDecember 2023August 2025Allow2021YesNo
18532876METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEXDecember 2023November 2025Allow2420NoNo
18527884USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERSDecember 2023March 2025Allow1510NoNo
18525495SOLID HAND AND BODY LOTION PELLETSNovember 2023August 2024Abandon810NoNo
18515201METHOD FOR PREPARING POLY(THIOCTIC ACID)-COPPER COATING ON SURFACE OF CARDIOVASCULAR STENT MATERIALNovember 2023November 2025Allow2300NoNo
18511042COMPOSITIONS AND METHODS FOR TREATING ANEMIANovember 2023October 2025Allow2320NoNo
18506493SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USENovember 2023June 2024Allow710NoNo
18504280AQUEOUS ORAL COMPOSITIONS INCLUDING POTASSIUM CHLORIDENovember 2023December 2025Allow2530NoNo
18503232Combination and Uses and Treatments ThereofNovember 2023April 2025Abandon1810NoNo
18386758METHOD OF TREATING A GLAZED CERAMIC ARTICLENovember 2023April 2025Allow1800NoNo
18500167PLASMONIC ENHANCED MAGNETIC NANOPARTICLES HYPERTHERMIANovember 2023October 2025Abandon2421NoNo
18386411ETHYL 2-[9-(6-FLOURO-2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow300NoNo
18492136MATERIALS AND METHODS FOR THE CONTROL OF NEMATODESOctober 2023July 2025Allow2111NoNo
183828879-(5-BROMO-2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow511NoNo
18492284DISINTEGRATING MONOLITHIC MODIFIED RELEASE TABLETS CONTAINING QUADRI-LAYER EXTENDED RELEASE GRANULESOctober 2023July 2025Abandon2111NoNo
18381436TOPICAL SKIN CARE FORMULATIONS COMPRISING PLANT EXTRACTSOctober 2023December 2025Allow2610NoNo
18286914NANOPARTICULATE COMPOSITIONSOctober 2023October 2025Allow2400YesNo
18379598Botanical Film-Forming Acne CompositionsOctober 2023June 2025Allow2010NoNo
18555193USE IN AN AQUEOUS-ALCOHOLIC COMPOSITION OF POLYMERS OBTAINED BY LOW-CONCENTRATION INVERSE EMULSION POLYMERISATION WITH LOW NEUTRALISED MONOMER LEVELOctober 2023November 2024Abandon1411NoNo
18483098FREEZE-DRIED ARIPIPRAZOLE FORMULATIONOctober 2023January 2025Abandon1610NoNo
18477212METHOD FOR SKIN PROTECTION BY USING A ZnO/NSP COMPOSITESeptember 2023October 2025Allow2500NoNo
18374334HOLLOW SILICA SPHERES WITH NESTED IRON OXIDE PARTICLESSeptember 2023February 2024Allow410YesNo
18475634SURFACE ZWITTERIONIZED SILICONE ANTIFOULING COATING AND PREPARATION METHOD THEREOFSeptember 2023March 2025Abandon1721NoNo
18370106INTERPENETRATING POLYMER NETWORK HYDROGELSeptember 2023October 2025Abandon2511NoNo
18282406COSMETIC COMPOSITIONSeptember 2023March 2026Abandon3001NoNo
18465918COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIASeptember 2023August 2024Abandon1111NoNo
18463029Hair Care Product and KitSeptember 2023February 2026Abandon2901NoNo
18242099Micronutrient composition to improve men healthSeptember 2023March 2024Allow610YesNo
18548700GADUSOL AND GADUSPORINE COMPOUND FORMULATIONS FOR TOPICALSSeptember 2023August 2025Abandon2431NoNo
18240438COMPOSITION COMPRISING A COMBINATION CONSISTING OF MAGNOLOL AND HONOKIOL, USE OF THE COMPOSITION, METHOD OF MANUFACTURING THE COMPOSITION, AND COSMETIC PRODUCTS COMPRISING THE COMPOSITION AND METHOD OF MANUFACTURING THEREOFAugust 2023February 2026Allow3011YesNo
18457668SILICONE INFUSED WITH SILVERAugust 2023August 2025Abandon2311NoNo
18456758METHODS FOR MAINTAINING CONCENTRATIONS OF VOLATILE LIPOPHILIC COMPOUNDS IN MANUFACTURE OF COMPOSITIONS AND DOSAGE FORMSAugust 2023January 2026Abandon2941NoNo
18239045COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAAugust 2023February 2026Allow2921NoYes
18456072WHITE PIGMENT FOR COSMETICS, AND COSMETICAugust 2023November 2024Abandon1510NoNo
18236612BIO-BASED MOISTURE ABSORPTION AND SWEAT DISCHARGING MULTIFUNCTIONAL FINISHING AGENT AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023February 2024Allow601NoNo
18236278COMPOSITION FOR PREVENTING ADHESION OF AIR-BORNE FINE PARTICLESAugust 2023April 2025Abandon2010NoNo
18233535MULTIPLE USE WOUND AND HEALING CREAMAugust 2023March 2026Abandon3101NoNo
18449358GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOFAugust 2023September 2025Abandon2511NoNo
18448259BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSAugust 2023April 2024Allow811NoNo
18448250BIOLOGIC MATRIX FOR A WOUND SITE AND RELATED METHODSAugust 2023July 2025Allow2341NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1619.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
471
Examiner Affirmed
358
(76.0%)
Examiner Reversed
113
(24.0%)
Reversal Percentile
12.7%
Lower than average

What This Means

With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1511
Allowed After Appeal Filing
271
(17.9%)
Not Allowed After Appeal Filing
1240
(82.1%)
Filing Benefit Percentile
3.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1619 - Prosecution Statistics Summary

Executive Summary

Art Unit 1619 is part of Group 1610 in Technology Center 1600. This art unit has examined 8,656 patent applications in our dataset, with an overall allowance rate of 36.6%. Applications typically reach final disposition in approximately 40 months.

Comparative Analysis

Art Unit 1619's allowance rate of 36.6% places it in the 2% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1619 receive an average of 2.78 office actions before reaching final disposition (in the 93% percentile). The median prosecution time is 40 months (in the 13% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for multiple rounds of prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.